| Literature DB >> 23533472 |
Francisco Fábio Martins de Oliveira1, Alba Fabiola Torres, Thially Braga Gonçalves, Gilvandete Maria Pinheiro Santiago, Cibele Barreto Mano de Carvalho, Milena Braga Aguiar, Lilia Maria Carneiro Camara, Silvia Helena Rabenhorst, Alice Maria Costa Martins, José Telmo Valença Junior, Aparecida Tiemi Nagao-Dias.
Abstract
The present work aimed to evaluate the effectiveness of Plectranthus amboinicus (Lour.) Spreng against MRSA clinical isolates. The in vitro antimicrobial activity of the hydroalcoholic extract (HE), the ethyl acetate (EA) fraction and its subfractions were determined by broth microdilution and bioautography against MRSA clinical isolates. The microdilution checkerboard method was used to assess in vitro drug combination studies. To induce abscess formation, bacterial suspensions were added to Citodex and inoculated subcutaneously into male Swiss mice. The treatment protocol consisted of 2 doses of HE, the EA fraction or vancomycin introduced intraperitoneally into mice 3 and 12 h after infection. The EA fraction and its subfractions presented the lowest minimal inhibitory concentrations (MIC, 0.25 to 0.5 mg/mL). The plant samples were bacteriostatic at 2x and 4x MIC and bactericidal at 100 mg/mL. The EA fraction presented synergism with vancomycin and an additive effect with ciprofloxacin. A significant reduction of abscess volume, bacterial cell counts in abscess slurries, and inflammatory scores was observed in the HE and EA fraction-treated groups. The samples were effective in treating the animals in a dose-dependent fashion. The present study proved the effectiveness of P. amboinicus fractions against MRSA using in vitro and in vivo assays.Entities:
Year: 2013 PMID: 23533472 PMCID: PMC3590755 DOI: 10.1155/2013/291592
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Partition of the ethanolic extract of Plectranthus amboinicus by using a column chromatography packed with silica gel 60 (70–230 mesh). Elution procedure was done with solvents of increasing polarities.
| Eluent | Volume (mL) | Quantity (g) | Fractions |
|---|---|---|---|
| Hex | 2000 | 2.3 | F1 |
| Ep | 2000 | 1.2 | F2 |
| DCM | 5000 | 35.9 | F3 |
| AcOEt | 5000 | 29.6 | F4 |
| MeOH | 2000 | 5.9 | F5 |
Hex: hexane; Ep: petroleum ether; DCM: dichloromethane; AcOEt: ethyl acetate; MeOH: methanol.
Partition of the ethyl acetate fraction F4 of Plectranthus amboinicus by using a column chromatography packed with silica gel 60 (70–230 mesh). Elution procedure was done with different ratios of hexane (Hex) and ethyl acetate (AcOEt).
| Eluent | Ratio (%) | Volume (mL) | Quantity (g) | Subfractions |
|---|---|---|---|---|
| Hex : AcOEt | 90 : 10 | 2000 | 2.1 | F4a |
| Hex : AcOEt | 80 : 20 | 2000 | 2.4 | F4b |
| Hex : AcOEt | 70 : 30 | 2000 | 3.2 | F4c |
| Hex : AcOEt | 60 : 40 | 1000 | 1.5 | F4d |
| Hex : AcOEt | 50 : 50 | 1000 | 1.1 | F4e |
| AcOEt | 100 | 1000 | 0.8 | F4f |
| MeOH | 100 | 2000 | 17.3 | F4g |
Resistance of Staphylococcus aureus clinical isolates to antimicrobial drugs. The tests were performed according to the CLSI recommendations [19]. The presence or absence of the genes mecA and CoA was verified by the polymerase chain reaction technique, according to the procedure described by Rallapalli et al. [20].
| Clinical isolates | Specimen | mecA gene | CoA gene | Antibiotic resistance |
|---|---|---|---|---|
| Strain 01 | BL | + | + | Amp, Chlo, Cip, Ery, Gen, Pen, Sul |
| Strain 02 | BL | + | + | Amp, Chlo, Pen, Sul, Tet |
| Strain 03 | BL | + | + | Amp, Chlo, Cip, Ery, Gen, Pen, Sul, Tet |
| Strain 04 | BL | + | + | Amp, Ery, Gen, Pen, Sul |
| Strain 05 | BL | + | + | Chlo, Ery, Gen, Pen, Tet |
| Strain 06 | BL | − | + | Amp, Chlo, Cip, Ery, Gen, Pen, Sul |
| Strain 07 | BL | + | + | Amp, Ery, Gen, Pen, Sul |
| Strain 08 | BL | + | + | Amp, Chlo, Pen, Sul, Tet |
| Strain 09 | BL | + | + | Amp, Gen, Pen, Sul, Tet |
| Strain 10 | BL | + | + | Amp, Chlo, Ery, Gen, Pen, Sul |
| Strain 11 | CT | + | + | Amp, Chlo, Ery, Gen, Pen, Tet |
| Strain 12 | WF | + | + | Amp, Ery, Gen, Pen, Sul, Tet |
| Strain 13 | CT | + | + | Amp, Chlo, Cip, Ery, Gen, Pen, Sul, Tet |
| Strain 14 | WF | + | + | Amp, Chlo, Cip, Ery, Gen, Pen, Sul, Tet |
Catheter tip (CT); blood (BL); wound fluid (WF) from diabetic foot ulcers. Pen: penicillin; Amp: ampicillin; Ery: erythromycin; Cip: ciprofloxacin; Gen: gentamicin; Chlo: chloramphenicol; Tet: tetracycline; Sul: sulfamethoxazole/trimethoprim; Van: vancomycin.
Minimal inhibitory concentration of extracts, fractions, and subfractions of P. amboinicus against MRSA clinical isolates and ATCC.
| Strain | Controls | Extracts | Fractions | Subfractions | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Van | DMSO | Bact | EH | ET | F1 | F2 | F3 | F4 | F5 | F4a | F4b | F4c | F4d | F4e | F4f | F4g | |
| ATCC 25923 | 1 | no | + | 4 | 8 | no | no | no | 0.5 | no | 2 | 0.5 | 0.5 | 0.5 | no | no | no |
| ATCC 65398 | 1 | no | + | 4 | 4 | no | no | no | 0.5 | no | 1 | 0.5 | 0.5 | 0.5 | no | no | no |
| MRSA 01 | 2 | no | + | 4 | 8 | no | no | no | 0.5 | no | 1 | 0.5 | 0.5 | 0.5 | no | no | no |
| MRSA 02 | 2 | no | + | 2 | 4 | no | no | no | 0.5 | no | 2 | 0.5 | 0.5 | 0.5 | no | no | no |
| MRSA 03 | 1 | no | + | 2 | 8 | no | no | no | 0.25 | no | 1 | 0.5 | 0.5 | 0.5 | no | no | no |
| MRSA 04 | 1 | no | + | 2 | 8 | no | no | no | 0.5 | no | |||||||
| MRSA 05 | 1 | no | + | 4 | 4 | no | no | no | 0.5 | no | |||||||
| MRSA 06 | 2 | no | + | 4 | 8 | no | no | no | 0.25 | no | |||||||
| MRSA 07 | 2 | no | + | 2 | 8 | no | no | no | 0.5 | no | |||||||
| MRSA 08 | 1 | no | + | 2 | 4 | no | no | no | 0.5 | no | |||||||
| MRSA 09 | 2 | no | + | 2 | 8 | no | no | no | 0.5 | no | |||||||
| MRSA 10 | 1 | no | + | 2 | 4 | no | no | no | 0.5 | no | |||||||
| MRSA 11 | 2 | no | + | 2 | 8 | no | no | no | 0.5 | no | |||||||
| MRSA 12 | 2 | no | + | 2 | 8 | no | no | no | 0.5 | no | |||||||
| MRSA 13 | 2 | no | + | 2 | 8 | no | no | no | 0.25 | no | |||||||
| MRSA 14 | 2 | no | + | 2 | 8 | no | no | no | 0.5 | no | |||||||
Bact: bacteria; CT: growth control; EH: hydroalcoholic extract; ET: ethanolic extract; F1: hexane fraction; F2: petroleum ether fraction; F3: dichloromethane fraction; F4: ethyl acetate fraction; F5: methanol fraction; F4a–g: subfractions of fraction F4; Van: vancomycin; DMSO: dimethyl sulfoxide; no: no activity.
Figure 1Bacteriostatic and bactericidal activities of the hydroalcoholic (HE) extract (a) and the ethyl acetate fraction F4 (b) from P. amboinicus against a standard MRSA strain (ATCC 65398). The results are expressed as log 10 colony-forming units/mL.
Figure 2Bioautography of the ethyl acetate F4 subfractions from P. amboinicus. Two thin-layer chromatography plates were tested as follows. (a) A developed thin-layer chromatography (TLC) plate was dipped into a Petri dish containing Mueller-Hinton agar previously inoculated with 106 CFU/mL of MRSA. After incubation, the plate was stained with thiazolyl blue tetrazolium MTT stain. (b) A developed TLC plate was directly stained with vanillin/perchloric acid. The arrows indicate the zones of bacterial growth inhibition. The solvent solution used for elution was hexane: ethyl acetate (6 : 4).
Mice infected subcutaneously with an MRSA clinical isolate (strain #08) and treated intra-peritoneally with hydroalcoholic extract (HE) or fraction F4 from P. amboinicus or with vancomycin. The results were expressed by bacterial growth (log colony-forming unities (CFU) per site), abscess volume mean (mm3), and by indices of the histopathological analysis.
| Treatment | Dosage | MIC | Abscess volume mean |
| Bacterial cell count |
| Histopathological analysis |
|
|---|---|---|---|---|---|---|---|---|
| Control | 130.0 ± 29.1 | 7.2 ± 0.41 | 11.4 ± 0.78 | |||||
| HE | 500 | 2.0 | 63.0 ± 26.7 | <0.01 | 5.6 ± 0.51 | <0.01 | 6.7 ± 2.9 | <0.01 |
| 250 | 99 | N.S. | 6.9 ± 0.48 | <0.05 | 9.3 ± 0.82 | N.S. | ||
| F4 | 500 | 0.5 | 26.9 ± 14.5 | <0.001 | 4.7 ± 0.89 | <0.001 | 5.4 ± 3.1 | <0.001 |
| 250 | 55.1 ± 11.8 | <0.001 | 5.3 ± 0.48 | <0.001 | 6.7 ± 2.7 | <0.01 | ||
| Vancomycin | 20 | 0.2 | 46.0 ± 22.9 | <0.001 | 4.2 ± 0.91 | <0.01 | 7.5 ± 1.6 | <0.01 |
| 10 | 82.7 ± 27.9 | <0.05 | 5.4 ± 0.86 | <0.05 | 7.8 ± 2.3 | <0.05 |
MIC: minimal inhibitory concentration; SD: standard deviation, N.S.: not significant.
Figure 3Volume of subcutaneous abscesses in mice infected with an MRSA clinical isolate strain (#08), 72 h after intraperitoneal treatment with 2 doses of ethyl acetate fraction F4 from P. amboinicus at 500 mg/kg/dose. (a) Untreated animal. (b) Animal treated with fraction F4.
(a) Hydroalcoholic extract (EH)
| CIF | ICIF | Interaction | CIF | IFIC | Interaction | |||
|---|---|---|---|---|---|---|---|---|
| Eh | Van | Eh | Cip | |||||
| ATCC (65398) | 1 | 1 | 2 | I | 0.5 | 2 | 2.5 | I |
| MRSA 05 | 1 | 2 | 3 | I | 0.5 | 2 | 2.5 | I |
| MRSA 08 | 1 | 1 | 2 | I | 0.5 | 2 | 2.5 | I |
| MRSA 12 | 1 | 1 | 2 | I | 0.5 | 2 | 2.5 | I |
(b) Ethyl acetate fraction (F4)
| CIF | ICIF | Interaction | CIF | IFIC | Interaction | |||
|---|---|---|---|---|---|---|---|---|
| F4 | Van | F4 | Cip | |||||
| ATCC (65398) | 0.5 | 0.25 | 0.75 | S | 0.5 | 0.5 | 1 | A |
| MRSA 05 | 0.5 | 0.25 | 0.75 | S | 0.5 | 0.5 | 1 | A |
| MRSA 08 | 0.5 | 0.25 | 0.75 | S | 0.5 | 0.5 | 1 | A |
| MRSA 12 | 0.5 | 0.25 | 0.75 | S | 0.5 | 0.5 | 1 | A |
CIF: fractional inhibitory concentration; ICIF: fractional inhibitory concentration index.